What is he best known for?
The fields of study he is best known for:
- Gene
- Enzyme
- Internal medicine
Peter J. Little mostly deals with Internal medicine, Endocrinology, Cell biology, Vascular smooth muscle and Signal transduction.
His study looks at the relationship between Internal medicine and fields such as Pharmacology, as well as how they intersect with chemical problems.
He combines subjects such as Troglitazone, Platelet-derived growth factor and Mesenteric arteries with his study of Endocrinology.
His research integrates issues of Biochemistry and Transcription factor in his study of Cell biology.
His study in Vascular smooth muscle is interdisciplinary in nature, drawing from both Blood vessel, Cell growth, Peroxisome proliferator-activated receptor, Platelet-derived growth factor receptor and Pioglitazone.
His Signal transduction study integrates concerns from other disciplines, such as Cancer, Dyslipidemia and Insulin resistance.
His most cited work include:
- Insulin resistance and atherosclerosis (249 citations)
- Cardiovascular actions and therapeutic potential of tanshinone IIA. (216 citations)
- Cloning and expression of a rabbit cDNA encoding a serum-activated ethylisopropylamiloride-resistant epithelial Na+/H+ exchanger isoform (NHE-2). (192 citations)
What are the main themes of his work throughout his whole career to date?
Peter J. Little mainly investigates Internal medicine, Endocrinology, Vascular smooth muscle, Cell biology and Biochemistry.
His Internal medicine research is multidisciplinary, incorporating perspectives in Diabetes mellitus and Pharmacology.
He interconnects Troglitazone and Endothelin 1 in the investigation of issues within Endocrinology.
The Vascular smooth muscle study which covers Glycosaminoglycan that intersects with Low-density lipoprotein.
His Cell biology research incorporates themes from Receptor and Transactivation.
The Transactivation study combines topics in areas such as Receptor tyrosine kinase, Signal transduction, G protein-coupled receptor kinase and Serine/threonine-specific protein kinase.
He most often published in these fields:
- Internal medicine (46.05%)
- Endocrinology (41.42%)
- Vascular smooth muscle (39.78%)
What were the highlights of his more recent work (between 2016-2021)?
- Cell biology (42.78%)
- Receptor (22.62%)
- G protein-coupled receptor (24.25%)
In recent papers he was focusing on the following fields of study:
Peter J. Little spends much of his time researching Cell biology, Receptor, G protein-coupled receptor, Phosphorylation and Kinase.
His Cell biology research includes elements of Transcription factor, Gene expression, Transactivation and Vascular smooth muscle.
The study incorporates disciplines such as Proteoglycan and G protein in addition to G protein-coupled receptor.
As a part of the same scientific family, Peter J. Little mostly works in the field of Phosphorylation, focusing on Biglycan and, on occasion, Glycosaminoglycan.
In Kinase, Peter J. Little works on issues like Serine, which are connected to Low-density lipoprotein.
His work in MAPK/ERK pathway covers topics such as Protein kinase B which are related to areas like Internal medicine.
Between 2016 and 2021, his most popular works were:
- FOXO Signaling Pathways as Therapeutic Targets in Cancer. (157 citations)
- Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen. (47 citations)
- Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen. (47 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Enzyme
- Internal medicine
His main research concerns Cell biology, Endothelial dysfunction, Pharmacology, Receptor and Inflammation.
His work carried out in the field of Cell biology brings together such families of science as Transcription factor and Vascular smooth muscle.
His Endothelial dysfunction research includes themes of Metformin, Cancer research, Coronary artery disease, Foam cell and Platelet activation.
The various areas that Peter J. Little examines in his Pharmacology study include Mechanism of action, Endothelium, Function and Molecular targets.
Many of his research projects under Receptor are closely connected to OLR1 with OLR1, tying the diverse disciplines of science together.
His G protein-coupled receptor research is under the purview of Biochemistry.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
